시장보고서
상품코드
1721213

말초동맥질환 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2035년)

Peripheral Arterial Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035

발행일: | 리서치사: Transparency Market Research | 페이지 정보: 영문 245 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

말초동맥질환 치료 시장 : 조사 범위

TMR의 보고서 "세계 말초동맥질환 치료 시장"은 2025-2035년 예측 기간 동안 시장 지표에 대한 귀중한 인사이트를 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사하고 있습니다. 이 보고서는 2019년부터 2035년까지의 세계 말초동맥질환 치료 시장의 수익과 예측을 제공하고자 2025년을 기준 연도로, 2035년을 예측 연도로 설정했습니다. 또한, 2025-2035년 세계 말초동맥질환 치료 시장의 CAGR%도 제공합니다.

이 보고서는 광범위한 조사를 통해 작성되었습니다. 1차 조사에서 애널리스트는 주요 오피니언 리더, 업계 리더, 오피니언 메이커를 대상으로 인터뷰를 진행했습니다. 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 자료 등을 참고하여 말초동맥질환 치료 시장을 이해하고자 했습니다.

시장 스냅샷
2024년 시장 규모 29억 달러
2035년 시장 규모 64억 달러
CAGR 7.5%

이 보고서는 세계 말초동맥질환 치료 시장의 경쟁 환경을 조사하고 있습니다. 세계 말초동맥질환 치료 시장에서 활동하는 주요 업체를 식별하고, 각 업체는 다양한 속성별로 프로파일을 작성했습니다. 기업 개요, 재무 상태, 최근 동향, SWOT 등 세계 말초동맥질환 치료 시장의 기업 속성이 본 보고서에서 소개됩니다.

목차

제1장 서문

제2장 가정과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

  • 소개
  • 개요
  • 시장 역학
  • 세계의 말초동맥질환 치료 시장 분석과 예측(2020-2035년)

제5장 주요 인사이트

  • 주요 지역/국가의 규제 상황
  • 시장 동향
  • Porter's Five Forces 분석
  • PESTEL 분석
  • 최종사용자에 대한 주요 구입 지표
  • 브랜드와 가격 분석
  • 치료 알고리즘
  • 주요 업계 이벤트

제6장 세계의 시장 분석과 예측 : 약물 유형별

  • 소개와 정의
  • 주요 조사 결과/진전
  • 시장 금액 예측 : 약물 유형별(2020-2035년)
    • 항혈소판제
    • 콜레스테롤 저하제(스타틴)
    • 강압제
    • 혈압약
    • 혈관확장제
    • 기타
  • 시장 매력 : 약물 유형별

제7장 세계의 시장 분석과 예측 : 투여 경로별

  • 소개와 정의
  • 주요 조사 결과/진전
  • 시장 금액 예측 : 투여 경로별(2020-2035년)
    • 경구
    • 비경구
  • 시장 매력 : 투여 경로별

제8장 세계의 시장 분석과 예측 : 유통 채널별

  • 소개와 정의
  • 주요 조사 결과/진전
  • 시장 금액 예측 : 유통 채널별(2020-2035년)
    • 원내 약국
    • 소매 약국
    • 온라인 약국
  • 시장 매력 : 유통 채널별

제9장 세계의 시장 분석과 예측 : 지역별

  • 주요 조사 결과
  • 시장 금액 예측 : 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 라틴아메리카
    • 중동 및 아프리카
  • 시장 매력 : 지역별

제10장 북미의 시장 분석과 예측

  • 미국
  • 캐나다

제11장 유럽의 시장 분석과 예측

  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽

제12장 아시아태평양의 시장 분석과 예측

  • 중국
  • 일본
  • 인도
  • 호주와 뉴질랜드
  • 기타 아시아태평양

제13장 라틴아메리카의 시장 분석과 예측

  • 브라질
  • 멕시코
  • 기타 라틴아메리카

제14장 중동 및 아프리카의 시장 분석과 예측

  • GCC 국가
  • 남아프리카공화국
  • 기타 중동 및 아프리카

제15장 경쟁 구도

  • 시장 기업 : 경쟁 매트릭스(기업 계층별·규모별)
  • 시장 점유율 분석 : 기업별(2024년)
  • 기업 개요
    • Bayer AG
    • Pfizer Inc.
    • Eli Lilly and Company
    • Cipla
    • Lupin
    • Viatris Inc
    • Johnson & Johnson Services, Inc.
    • Sanofi
    • Novartis AG
    • Amgen Inc.
    • Aurobindo Pharma Limited
    • 기타
ksm 25.06.09

Peripheral Arterial Disease Treatment Market - Scope of Report

TMR's report on the global peripheral arterial disease treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global peripheral arterial disease treatment market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global peripheral arterial disease treatment market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the peripheral arterial disease treatment market.

Market Snapshot
Market Value in 2024US$ 2.9 Bn
Market Value in 2035US$ 6.4 Bn
CAGR7.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global peripheral arterial disease treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global peripheral arterial disease treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global peripheral arterial disease treatment market.

The report delves into the competitive landscape of the global peripheral arterial disease treatment market. Key players operating in the global peripheral arterial disease treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global peripheral arterial disease treatment market profiled in this report.

Key Questions Answered in Global peripheral arterial disease treatment market Report:

  • What is the sales/revenue generated by peripheral arterial disease treatment across all regions during the forecast period?
  • What are the opportunities in the global peripheral arterial disease treatment market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2035?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Peripheral Arterial Disease Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global peripheral arterial disease treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global peripheral arterial disease treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global peripheral arterial disease treatment market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Peripheral Arterial Disease Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Peripheral Arterial Disease Treatment Market Analysis and Forecasts, 2020-2035
    • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

  • 5.1. Regulatory Landscape across Key Regions / Countries
  • 5.2. Market Trends
  • 5.3. PORTER's Five Forces Analysis
  • 5.4. PESTEL Analysis
  • 5.5. Key Purchase Metrics for End-users
  • 5.6. Brand and Pricing Analysis
  • 5.7. Treatment Algorithm
  • 5.8. Key Industry Events

6. Global Peripheral Arterial Disease Treatment Market Analysis and Forecasts, By Drug Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Drug Type, 2020-2035
    • 6.3.1. Antiplatelet Drugs
    • 6.3.2. Cholesterol-Lowering Drugs (Statins)
    • 6.3.3. Anti-hypertensive Drugs
    • 6.3.4. Blood Pressure Medications
    • 6.3.5. Vasodilators
    • 6.3.6. Others
  • 6.4. Market Attractiveness By Drug Type

7. Global Peripheral Arterial Disease Treatment Market Analysis and Forecasts, By Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Route of Administration, 2020-2035
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Market Attractiveness By Route of Administration

8. Global Peripheral Arterial Disease Treatment Market Analysis and Forecasts, By Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Distribution Channel, 2020-2035
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness By Distribution Channel

9. Global Peripheral Arterial Disease Treatment Market Analysis and Forecasts, By Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast By Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness By Region

10. North America Peripheral Arterial Disease Treatment Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast By Drug Type, 2020-2035
    • 10.2.1. Antiplatelet Drugs
    • 10.2.2. Cholesterol-Lowering Drugs (Statins)
    • 10.2.3. Anti-hypertensive Drugs
    • 10.2.4. Blood Pressure Medications
    • 10.2.5. Vasodilators
    • 10.2.6. Others
  • 10.3. Market Value Forecast By Route of Administration, 2020-2035
    • 10.3.1. Oral
    • 10.3.2. Parenteral
  • 10.4. Market Value Forecast By Distribution Channel, 2020-2035
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast By Country, 2020-2035
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Type
    • 10.6.2. By Route of Administration
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Peripheral Arterial Disease Treatment Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Drug Type, 2020-2035
    • 11.2.1. Antiplatelet Drugs
    • 11.2.2. Cholesterol-Lowering Drugs (Statins)
    • 11.2.3. Anti-hypertensive Drugs
    • 11.2.4. Blood Pressure Medications
    • 11.2.5. Vasodilators
    • 11.2.6. Others
  • 11.3. Market Value Forecast By Route of Administration, 2020-2035
    • 11.3.1. Oral
    • 11.3.2. Parenteral
  • 11.4. Market Value Forecast By Distribution Channel, 2020-2035
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast By Country/Sub-region, 2020-2035
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Type
    • 11.6.2. By Route of Administration
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Peripheral Arterial Disease Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Drug Type, 2020-2035
    • 12.2.1. Antiplatelet Drugs
    • 12.2.2. Cholesterol-Lowering Drugs (Statins)
    • 12.2.3. Anti-hypertensive Drugs
    • 12.2.4. Blood Pressure Medications
    • 12.2.5. Vasodilators
    • 12.2.6. Others
  • 12.3. Market Value Forecast By Route of Administration, 2020-2035
    • 12.3.1. Oral
    • 12.3.2. Parenteral
  • 12.4. Market Value Forecast By Distribution Channel, 2020-2035
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast By Country/Sub-region, 2020-2035
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Type
    • 12.6.2. By Route of Administration
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Peripheral Arterial Disease Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Drug Type, 2020-2035
    • 13.2.1. Antiplatelet Drugs
    • 13.2.2. Cholesterol-Lowering Drugs (Statins)
    • 13.2.3. Anti-hypertensive Drugs
    • 13.2.4. Blood Pressure Medications
    • 13.2.5. Vasodilators
    • 13.2.6. Others
  • 13.3. Market Value Forecast By Route of Administration, 2020-2035
    • 13.3.1. Oral
    • 13.3.2. Parenteral
  • 13.4. Market Value Forecast By Distribution Channel, 2020-2035
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast By Country/Sub-region, 2020-2035
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Type
    • 13.6.2. By Route of Administration
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Peripheral Arterial Disease Treatment Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Drug Type, 2020-2035
    • 14.2.1. Antiplatelet Drugs
    • 14.2.2. Cholesterol-Lowering Drugs (Statins)
    • 14.2.3. Anti-hypertensive Drugs
    • 14.2.4. Blood Pressure Medications
    • 14.2.5. Vasodilators
    • 14.2.6. Others
  • 14.3. Market Value Forecast By Route of Administration, 2020-2035
    • 14.3.1. Oral
    • 14.3.2. Parenteral
  • 14.4. Market Value Forecast By Distribution Channel, 2020-2035
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast By Country/Sub-region, 2020-2035
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Drug Type
    • 14.6.2. By Route of Administration
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 15.2. Market Share Analysis By Company (2024)
  • 15.3. Company Profiles
    • 15.3.1. Bayer AG
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Financial Overview
      • 15.3.1.3. Product Portfolio
      • 15.3.1.4. Business Strategies
      • 15.3.1.5. Recent Developments
    • 15.3.2. Pfizer Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Financial Overview
      • 15.3.2.3. Product Portfolio
      • 15.3.2.4. Business Strategies
      • 15.3.2.5. Recent Developments
    • 15.3.3. Eli Lilly and Company
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Financial Overview
      • 15.3.3.3. Product Portfolio
      • 15.3.3.4. Business Strategies
      • 15.3.3.5. Recent Developments
    • 15.3.4. Cipla
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Financial Overview
      • 15.3.4.3. Product Portfolio
      • 15.3.4.4. Business Strategies
      • 15.3.4.5. Recent Developments
    • 15.3.5. Lupin
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Financial Overview
      • 15.3.5.3. Product Portfolio
      • 15.3.5.4. Business Strategies
      • 15.3.5.5. Recent Developments
    • 15.3.6. Viatris Inc
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Financial Overview
      • 15.3.6.3. Product Portfolio
      • 15.3.6.4. Business Strategies
      • 15.3.6.5. Recent Developments
    • 15.3.7. Johnson & Johnson Services, Inc.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Financial Overview
      • 15.3.7.3. Product Portfolio
      • 15.3.7.4. Business Strategies
      • 15.3.7.5. Recent Developments
    • 15.3.8. Sanofi
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Financial Overview
      • 15.3.8.3. Product Portfolio
      • 15.3.8.4. Business Strategies
      • 15.3.8.5. Recent Developments
    • 15.3.9. Novartis AG
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Financial Overview
      • 15.3.9.3. Product Portfolio
      • 15.3.9.4. Business Strategies
      • 15.3.9.5. Recent Developments
    • 15.3.10. Amgen Inc.
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Financial Overview
      • 15.3.10.3. Product Portfolio
      • 15.3.10.4. Business Strategies
      • 15.3.10.5. Recent Developments
    • 15.3.11. Aurobindo Pharma Limited
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Financial Overview
      • 15.3.11.3. Product Portfolio
      • 15.3.11.4. Business Strategies
      • 15.3.11.5. Recent Developments
    • 15.3.12. Other Prominent Players
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Financial Overview
      • 15.3.12.3. Product Portfolio
      • 15.3.12.4. Business Strategies
      • 15.3.12.5. Recent Developments
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제